The drug binding site of human α1-acid glycoprotein: Insight from induced circular dichroism and electronic absorption spectra

Biochimica et Biophysica Acta - General Subjects

Volumn 1770, Issue 5, 2007, Pages 797-809

  Zsila, Ferenc ^a   Iwao, Yasunori ^b  

^a CHEMICAL RESEARCH CENTER   (Hungary)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Barrel; Human serum 1 acid glycoprotein; Induced circular dichroism; Ligand binding; Lipocalin; Non degenerate exciton coupling; Tryptophan mutants

Indexed keywords

ALANINE; CARBAMAZEPINE; CHLORPROMAZINE; DIPYRIDAMOLE; INDOLE; LIPOCALIN; MEFLOQUINE; MUTANT PROTEIN; OROSOMUCOID; PRAZOSIN; PRIMAQUINE; PROPRANOLOL; RECOMBINANT PROTEIN; RHODAMINE B; TERAZOSIN; TRYPTOPHAN;

ABSORPTION SPECTROPHOTOMETRY; AMINO ACID SUBSTITUTION; ARTICLE; BETA CHAIN; BINDING AFFINITY; CHIRALITY; CIRCULAR DICHROISM; CONTROLLED STUDY; DRUG BINDING SITE; DRUG PROTEIN BINDING; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE;

ANTIPSYCHOTIC AGENTS; BINDING SITES; BUFFERS; CHLORPROMAZINE; CIRCULAR DICHROISM; HUMANS; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; MUTATION; OROSOMUCOID; PHARMACEUTICAL PREPARATIONS; PICHIA; PROTEIN BINDING; RECOMBINANT PROTEINS; SPECTROPHOTOMETRY, ULTRAVIOLET; TEMPERATURE; TRYPTOPHAN; WATER;

EID: 33947123212     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.01.009     Document Type: Article

References (67)

1. de Wolf F.A., and Brett G.M. Ligand-binding proteins: their potential for application in systems for controlled delivery and uptake of ligands. Pharmacol. Rev. 52 (2000) 207-236
2. Otagiri M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab. Pharmacokineti. 20 (2005) 309-323
3. 1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 33 (2001) 161-235
4. Yuasa I., Umetsu K., Vogt U., Nakamura H., Nanba E., Tamaki N., and Irizawa Y. Human orosomucoid polymorphism: molecular basis of the three common ORM1 alleles, ORM1*F1, ORM1*F2, and ORM1*S. Hum. Genet. 99 (1997) 393-398
5. 1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol. Pharmacol. 54 (1998) 129-138
6. 1-acid glycoprotein variants. Br. J. Clin. Pharmacol. 56 (2003) 664-669
7. 1-acid glycoprotein studied by circular dichroism spectroscopy. Biochem. Pharmacol. 67 (2004) 679-688
8. 1-acid glycoprotein and its high-affinity binding site. Biochem. Biophys. Res. Commun. 300 (2003) 41-46
9. 1-acid glycoprotein. Carbohydr. Res. 341 (2006) 2557-2564
10. Breustedt D.A., Schonfeld D.L., and Skerra A. Comparative ligand-binding analysis of ten human lipocalins. Biochim. Biophys. Acta 1764 (2006) 161-173
11. 1-acid glycoprotein. Biochim. Biophys. Acta 1760 (2006) 1704-1712
12. 1-acid glycoprotein. Bioorg. Chem. 33 (2005) 298-309
13. 1-acid glycoprotein. Bioorg. Med. Chem. 12 (2004) 3239-3245
14. 1-acid glycoprotein (orosomucoid). J. Pharm. Pharmacol. 34 (1982) 152-157
15. 1-acid glycoprotein, orosomucoid. J. Pharm. Sci. 72 (1983) 202-205
16. 1-acid glycoprotein (orosomucoid), human serum albumin, and human serum. Further characterization of the 'single drug binding site' of orosomucoid. J. Pharm. Pharmacol. 37 (1985) 305-309
17. 1-acid glycoprotein studied by circular dichroism. Pharm. Res. 6 (1989) 156-159
18. 1-acid glycoprotein systems by phenothiazine neuroleptics through ternary complexation. Pharm. Res. 9 (1992) 845-849
19. 1-acid glycoprotein systems by protriptyline. Biochem. Pharmacol. 43 (1992) 2161-2167
20. 1-acid glycoprotein. Biochem. Pharmacol. 42 (1991) 729-733
21. 1-acid glycoprotein. Chem. Pharm. Bull. 38 (1990) 1688-1691
22. 1-acid glycoprotein and human albumin. J. Pharm. Pharmacol. 39 (1987) 416-420
23. 1-acid glycoprotein. J. Biol. Chem. 280 (2005) 1384-1391
24. Schmid K. Preparation and properties of serum and plasma proteins. XXIX. Separation from human plasma of polysaccharides, peptides and proteins of low molecular weight. Crystallization of an acid glycoprotein. J. Am. Chem. Soc. 75 (1953) 60-68
25. 1-acid glycoprotein. J. Pharm. Sci. 90 (2001) 1407-1423
26. 1-acid glycoprotein. Pharmacogenetics 6 (1996) 403-415
27. Schaper W. Dipyridamole, an underestimated vascular protective drug. Cardiovasc. Drugs Ther. 19 (2005) 357-363
28. Borisevitch I.E., and Tabak M. Electronic absorption and fluorescence spectroscopic studies of dipyridamole: effects of solution composition. J. Lumin. 51 (1992) 315-322
29. Borges C.P.F., Honda S., Berlinck R.G.S., Imasato H., Berci P., and Tabak M. Synthesis, characterization and interaction with ionic micelles of tetraacetylated dipyridamole. Spectrochim. Acta, A 51 (1995) 2575-2584
30. Sonders R.C. Pharmacokinetics of terazosin. Am. J. Med. 80 (1986) 20-24
31. 1-acid glycoprotein. J. Pharm. Sci. 89 (2000) 751-757
32. 1-acid glycoprotein. J. Lab. Clin. Med. 116 (1990) 871-878
33. 1-acid glycoprotein chiral stationary phase: evidence for a multiple-site chiral recognition mechanism. Chirality 4 (1992) 30-35
34. 1-acid glycoprotein. Br. J. Clin. Pharmacol. 18 (1984) 487-493
35. Bandoli G., Nicolini M., Ongaro A., Volpe G., and Rubello A. X-ray crystallographic characterization of 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. J. Crystallogr. Spectrosc. Res. 22 (1992) 177-183
36. Ajtai K., and Burghardt T.P. Conformation of xanthene dyes in the sulfhydryl 1 binding site of myosin 2. Biochemistry 34 (1995) 15943-15952
37. Ishibashi K., Sato O., Baba R., Tryk D.A., Hashimoto K., and Fujishima A. Characterization of the chromophore orientation of rhodamine B amphiphiles in Langmuir-Blodgett monolayers. J. Colloid Interface Sci. 233 (2001) 361-363
38. Polyakova I.N., Starikova Z.A., Parusnikov B.V., and Krasavin I.A. Crystal structure of the 1:2.5 molecular complex of the internal salt of [6-(diethylamino)-9-[2-(fluorosulfonyl)-4-sulfophenyl]-3h-xanthen-3-ylidene]diethylammonium hydroxide with ethanol. J. Struct. Chem. 26 (1985) 600-605
39. Tetin S.Y., and Hazlett T.L. Optical spectroscopy in studies of antibody-hapten interactions. Methods 20 (2000) 341-361
40. 1-acid glycoprotein studied by circular dichroism and electronic absorption spectroscopy: the essential role of the conserved tryptophan residue. Biochim. Biophys. Acta 1760 (2006) 1248-1273
41. Zsila F., Bikádi Z., and Simonyi M. Induced chirality upon crocetin binding to human serum albumin: origin and nature. Tetrahedron: Asymmetry 12 (2001) 3125-3137
42. Sreerama N., and Woody R.W. Computation and analysis of protein circular dichroism spectra. Methods Enzymol. 383 (2004) 318-351
43. Jackson K., and Mason S.F. Linear and circular dichroism studies of DNA-monoaminoacridine complexes. Trans. Faraday Soc. 67 (1971) 966-989
44. Nishino H., Kosaka A., Hembury G.A., Matsushima K., and Inoue Y. The pH dependence of the anisotropy factors of essential amino acids. J. Chem. Soc., Perkin. Trans. 2 (2002) 582-590
45. Heyn M.P. Dependence of exciton circular dichroism amplitudes on oscillator strength. J. Phys. Chem. 79 (1975) 2424-2426
46. Harada N., Chen S.L., and Nakanishi K. Quantitative definition of exciton chirality and the distant effect in the exciton chirality method. J. Am. Chem. Soc. 97 (1975) 5345-5352
47. Friedman M.L., Schlueter K.T., Kirley T.L., and Halsall H.B. Fluorescence quenching of human orosomucoid. Accessibility to drugs and small quenching agents. Biochem. J. 232 (1985) 863-867
48. Villalobos A.P., Ivancic J.S., and Halsall H.B. The lipocalin model for human orosomucoid: support from the chromatography of orosomucoid-monoclonal antibody complexes. Chromatographia 39 (1994) 475-480
49. 1-acid glycoprotein. Prog. Clin. Biol. Res. 300 (1989) 363-378
50. Kremer J.M., Wilting J., and Janssen L.H. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40 (1988) 1-47
51. 1-acid glycoprotein (orosomucoid). Straightforward fluorescence experiments revealing the presence of a binding pocket. Carbohydr. Res. 339 (2004) 607-612
52. J.P. Schwegmann, The study of tryptophan residues in human orosomucoid and their involvement in the basic drug binding site, M.Sc. Thesis, University of Cincinnati, Cincinnati, United States, 1985.
53. Kalal P., and Kalous V. The tyrosyl and tryptophyl residues of orosomucoid studied by difference and derivative spectrophotometry. Collect. Czechoslov. Chem. Commun. 49 (1984) 165-169
54. 1-acid glycoprotein. Biochemistry 15 (1976) 2245-2254
55. Friedman M.L., Schwegmann J.P., Magnotti R.A., Schlueter K.T., and Halsall H.B. The basic drug-binding site of human orosomucoid. Biophys. J. 47 (1985) A409
56. Halsall H.B., and Kirley T.L. Fluorescence studies of the interaction of basic drugs with human orosomucoid. Biophys. J. 41 (1983) A268
57. 1-acid glycoprotein. J. Pharm. Pharmacol. 44 (1992) 28-33
58. Halsall H.B., Villalobos A.P., Ivancic J.S., Bencosme A.I., and Chung P. Monoclonal antibodies against human orosomucoid: tools for the exploration of structure, function and interactions. Prog. Clin. Biol. Res. 300 (1989) 67-84
59. 1-acid glycoprotein. J. Pharm. Pharmacol. 39 (1987) 132-134
60. A.I. Bencosme, Photoaffinity labelling the basic binding site of orosomucoid, Ph.D. Thesis University of Cincinnati, Cincinnati, United States, 1992.
61. 1-acid glycoprotein for characterization of the progesterone binding site. Biochim. Biophys. Acta 420 (1976) 195-213
62. J.A. Wallace, Photoaffinity labeling of the progesterone binding site of human orosomucoid, PhD thesis, University of Cincinnati, Cincinnati, United States, 1982.
63. McNamara P.J., Brouwer K.R., and Gillespie M.N. Autacoid binding to serum proteins. Interaction of platelet activating factor (PAF) with human serum alpha-1-acid glycoprotein (AAG). Biochem. Pharmacol. 35 (1986) 621-624
64. Müller W.E., and Stillbauer A.E. Characterization of a common binding site for basic drugs on human alpha1-acid glycoprotein (orosomucoid). Naunyn-Schmiedeberg's Arch. Pharmacol. 322 (1983) 170-173
65. Ferry D.G., Caplan N.B., and Cubeddu L.X. Interaction between antidepressants and alpha1-adrenergic receptor antagonists on the binding to alpha1-acid glycoprotein. J. Pharm. Sci. 75 (1986) 146-149
66. Bell J.D., Blount J.F., Briscoe O.V., and Freeman H.C. The crystal structure of phenothiazine. Chem. Commun. (1968) 1656-1657
67. Saito Y.D., Tehrani S., Okamoto M.M., Chang H.H., and Dea P. Calorimetry studies of chlorpromazine hydrochloride in solution. Langmuir 16 (2000) 6391-6395